Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV

Key Points

• Kornitzer Capital Management boosted its stake in AbbVie by 22.7%, purchasing 5,020 shares to hold 27,136 shares worth about $6.2 million at the end of the quarter.
• AbbVie beat Q1 estimates (EPS $2.65 vs. $2.59; revenue $15B vs. $14.72B), raised its 2026 outlook, and saw multiple analyst upgrades, leaving a consensus rating of “Moderate Buy” with a $252.90 target.
• The company announced a quarterly dividend of $1.73 (annualized $6.92, ~3.3% yield), while insiders sold shares (EVP sold 22,381) and institutional investors own roughly 70.23% of the stock.

Kornitzer Capital Management Inc. KS boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 22.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,136 shares of the company's stock after purchasing an additional 5,020 shares during the period. Kornitzer Capital Management Inc. KS's holdings in AbbVie were worth $6,200,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Centennial Wealth Advisory LLC lifted its stake in AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock worth $484,000 after purchasing an additional 45 shares during the last quarter. Weil Company Inc. lifted its stake in AbbVie by 2.3% during the third quarter. Weil Company Inc. now owns 2,026 shares of the company's stock worth $469,000 after purchasing an additional 46 shares during the last quarter. Hardin Capital Partners LLC lifted its stake in AbbVie by 1.4% during the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company's stock worth $759,000 after purchasing an additional 46 shares during the last quarter. Inlet Private Wealth LLC lifted its stake in AbbVie by 0.3% during the third quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company's stock worth $3,937,000 after purchasing an additional 47 shares during the last quarter. Finally, D.B. Root & Company LLC lifted its stake in shares of AbbVie by 4.3% in the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company's stock valued at $267,000 after acquiring an additional 47 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target for the company. Canaccord Genuity Group increased their price target on AbbVie from $262.00 to $265.00 and gave the company a "buy" rating in a research note on Thursday. William Blair reiterated an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $252.90.

AbbVie Stock Down 2.2%

Shares of NYSE:ABBV opened at $206.63 on Friday. The firm has a market cap of $365.36 billion, a P/E ratio of 101.79, a P/E/G ratio of 0.74 and a beta of 0.32. AbbVie Inc. has a 12-month low of $176.57 and a 12-month high of $244.81. The business has a fifty day simple moving average of $214.55 and a 200 day simple moving average of $221.54.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.AbbVie's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the company earned $2.46 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 14.29 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 340.89%.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by company insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.